Martina Kinzig‐Schippers

Should We Use <i>N</i> -Acetyltransferase Type 2 Genotyping To Personalize Isoniazid Doses?

Martina Kinzig‐Schippers, Dorota Tomalik‐Scharte, Alexander Jetter et al. · Antimicrobial Agents and Chemotherapy · 2005 · 198 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Toxicokinetics of Acrylamide in Humans after Ingestion of a Defined Dose in a Test Meal to Improve Risk Assessment for Acrylamide Carcinogenicity

Uwe Fuhr, Melanie I. Boettcher, Martina Kinzig‐Schippers et al. · Cancer Epidemiology Biomarkers & Prevention · 2006 · 182 citations

Pharmacy, Pharmacokinetics, Toxicology +13

Population Pharmacokinetics and Pharmacodynamics of Continuous versus Short-Term Infusion of Imipenem-Cilastatin in Critically Ill Patients in a Randomized, Controlled Trial

Samir G. Sakka, Anna K. Glauner, Jürgen B. Bulitta et al. · Antimicrobial Agents and Chemotherapy · 2007 · 153 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Evaluation by Monte Carlo Simulation of the Pharmacokinetics of Two Doses of Meropenem Administered Intermittently or as a Continuous Infusion in Healthy Volunteers

Wolfgang A. Krueger, Jürgen B. Bulitta, Martina Kinzig‐Schippers et al. · Antimicrobial Agents and Chemotherapy · 2005 · 104 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500mg) versus ciprofloxacin (500mg) in healthy volunteers receiving a single oral dose

Florian Wagenlehner, Martina Kinzig‐Schippers, Fritz Sörgel et al. · International Journal of Antimicrobial Agents · 2006 · 85 citations

Medicine, Pharmacokinetics, Pharmacology +13